Summan A randomised clinical trial has been conducted to compare adjuvant tamoxifen. 20 mg daily. with tamoxifen and prednisolone. 7.5 mg daily. in post-menopausal women with operable breast cancer. There were 254 evaluable patients. of whom 128 were given tamoxifen alone and 126 received tamoxifen and prednisolone. After a median follow-up of 48 months there was no significant difference in relapse-free or overall survival of the two groups. Furthermore, with survival slightly favouring tamoxifen. confidence intervals on the hazard ratio established that a difference in favour of tamoxifen plus prednisolone of even 5% at 5 years was very unlikely (P<0.02) Thus. despite the relatively small number of patients in this trial. the data clearly establish that prednisolone is not of value as an additional adjuvant agent.
As a result of the overview of adjuvant trials for patients with early beast cancer there is now a general agreement that post-menopausal women benefit from adjuvant tamoxifen (EBCTG. 1992) . Overall. tamoxifen produces a 25% reduction in the annual odds of relapse and a 17% reduction in the annual odds of death from breast cancer. A reduction in mortality was first demonstrated by the Nolvadex Adjuvant Trial Organisation (NATO. 1988) .
The benefits of tamoxifen are seen in patients with either node-positive of node-negative disease. The main benefit is seen in those with oestrogen receptor (ER)-positive tumours, but there is a small effect in those with ER-negative cancers (NATO. 1988) . Thus, most post-menopausal patients are now being given tamoxifen.
In order to try and increase the benefits of tamoxifen. we have conducted an adjuvant trial comparing tamoxifen alone against tamoxifen and prednisolone. The rationale for the study arose from a trial which had shown that prednisolone is of value in women with advanced breast cancer (Rubens et al.. 1988) . In this trial, which included 220 patients. premenopausal women received ovarian irradiation and postmenopausal women were given tamoxifen. They were randomised to have primary endocrine therapy either alone or with prednisolone 5 mg twice daily. Among those given primary endocrine therapy alone, a complete or partial response was seen in 30% compared with 49% for those given primary endocrine therapy and prednisolone. The median duration of response was increased from 9 to 14 months by prednisolone and the median time to disease progression increased from 5 to 9 months.
Additional evidence that prednisolone was beneficial as an adjuvant treatment was provided by the Princess Margaret Hospital trial (Meakin et al., 1979) . A group of 224 premenopausal women aged over 45 were given postoperative radiotherapy following mastectomy. They were randomised to no further treatment (66), ovarian irradiation (78) or ovarian irradiation and prednisolone 7.5 mg daily (80). After 10 years of follow-up the relapse-free and overall survival of the group given prednisolone was significantly better than that of the other two groups.
These data suggested that the addition of prednisolone might be beneficial. This 
Materials and methods
To be eligible for the trial patients had to be post-menopausal (no periods for the previous 6 months) or A total of 370 women were entered into the trial, 269 from Guy's and 101 from Withington Hospital. The characteristics of the patients from the two hospitals are given in Table I .
Overall, 29 patients were deemed eligible and were therefore randomised in error, of whom 20 were premenopausal. Other reasons for ineligibility were prior use of prednisolone (2). contraindication to steroids (2), non-invasive cancer (1). prior carcinoma (2) or age over 70 years (2) .
Surgery at Guy's comprised either a modified radical mastectomy in patients with tumours greater than 4 cm diameter or breast conservation therapy for those with smaller primary tumours. Breast conservation therapy comprised tumourectomy, axillary clearance and radiotherapy. At Withington Hospital patients were treated by total mastectomy or by breast conservation comprising wide excision followed by radiotherapy.
Patients who gave informed consent were randomised into the study within 10 days of surgery being performed. They were followed up at a special adjuvant therapy clinic and seen every 3 months for 3 years, then 6 monthly for the next 2 years and thereafter annually. Full blood count and biochemical screen were performed every 6 months together with a chest radiograph. Mammograms and radioisotopic bone scans were performed annually. Patients who developed local relapse had histological confirmation of the diagnosis. Those with distant relapse had radiological verification.
Statistical methods Survival and response durations were calculated using the method of Kaplan and Meier (1958) , with significance being evaluated using the log-rank test (Peto et al.. 1977) .
Trial size calculations used when designing the trial employed the method described by Freedman (1982 Fige I Relapse-free survival of both Guy's and Withington Hospital patients given either tamoxifen alone or tamoxifen and prednisolone.
reduction in the P-value necessary for stopping the trial to 0.025. With the trial giving a negative result, the confidence intervals of the hazard ratio between the two arms were calculated as suggested by Haybittle (1979) .
Results
Of the patients who were randomised to receive tamoxifen, treatment was stopped in five cases because of tiredness, cramp, weight gain and severe hot flushes. Dosage of tamoxifen was reduced to 10 mg daily in one patient who had hot flushes. In contrast, prednisolone was stopped in 39 patients, the reasons being weight gain (11), dyspepsia (11), diabetes (2), patient's wish (3), Cushingoid features (2), bruising (1), osteoporosis (1), visual problems (2), malaise (1), error (3), infection (1), and cerebrovascular accident (1). Prednisolone dosage was reduced in 12 patients because of weight gain (2), dyspepsia (5), hypertension (4) and hirsutism (1).
The relapse-free survival of the entire group of patients from both hospitals, as randomised, is shown in Figure 1 . No significant difference was seen. Similarly, in terms of survival no statistically significant difference was seen, although there was a trend towards a worse survival among those given tamoxifen and prednisolone, as shown in Figure 2 .
It is insufficient to report just the P-value from a negative trial, since this gives no information about the size of the difference that may still have been missed. By estimating the hazard ratio, with associated confidence limits, confidence limits can be produced for the difference at any particular time (Haybittle, 1979) . The hazard ratio for survival was in fact 1.32 (in favour of tamoxifen alone) with 95% confidence limits of 0.82-2.13. The survival rate at 5 years in the tamoxifen alone arm was 73%. Using this as a baseline, and the two values for the hazard ratio just calculated, gives a range of 51-77% for the tamoxifen plus prednisolone arm at 5 years. Thus, there is a I in 40 chance of tamoxifen plus prednisolone being 4% better at 5 years. In a similar way it can be calculated that there is only a I in 55 chance of tamoxifen plus prednisolone being 5% better at 5 years, and only a I in 2,000 chance of tamoxifen plus prednisolone being 10% better at 5 years.
The purpose of this study was to determine whether prednisolone conveyed additional benefit in women given adjuvant tamoxifen. Since recruitment to this trial was slowing down, an interim analysis was carried out, at which point Time (years)
Figue 2 Overall survival of Guy's and Withington Hospital cases given either tamoxifen alone or tamoxifen and prednisolone.
the trial was to have been stopped if a difference had emerged (at a significance level of 0.025) (Pocock, 1983) tamoxifen and prednisolone 7.5 mg daily. After a median follow-up of 26 months there were no significant differences in terms of either relapse-free or overall survival. Another negative trial has been reported in which tamoxifen and placebo was compared with tamoxifen and prednisolone in women with metastatic breast cancer (Ingle et al., 1991) . There was no significant association between treatment and outcome on covariate analyses. Similarly. the Ludwig group found no benefit from adding prednisone to adjuvant chemotherapy comprising cyclophosphamide, methotrexate and fluorouracil (Goldhirsch et al.. 1986) .
Of further concern, there were significantly more sideeffects among those women who received additional prednisolone, particularly weight gain, dyspepsia and fluid retention. A previous study on patients in this trial demonstrated that tamoxifen protects against potential steroid-induced bone loss. with no significant differences in bone mineral content of those given tamoxifen or tamoxifen and prednisolone after a minimum follow-up of 2 years (Fentiman et al.. 1992) . Thus, although tamoxifen is of proven benefit in an adjuvant role for post-menopausal women at risk of relapse of breast cancer, the results of this study suggest that this cannot be amplified by additional prednisolone.
